BREAKING: CTXR SURGING 15% ON EXPLOSIVE VOLUME!

The move we've been anticipating looks to be happening RIGHT NOW! 

While others are just discovering CTXR, our community appears well positioned for what analysts project could be a massive 264% upside. (8)

(8)

The volume today is off the charts, confirming strong interest in this potential breakout!

Remember: The last time we saw volume like this, early movers caught the biggest. 

With multiple catalysts lined up and analysts projecting a $9.00 target from today's $2.47, this could be just the beginning. (1)(6)

(6)

The last time we spotted numbers like these, our community watched their pick surge double digits in a single day.

🫨 But here's what's really turning heads: (2)(4)

• Stellar ratings across multiple analysts ⭐
• Jaw-dropping 48.07% projected annual earnings growth 🌱
• Enterprise value of just $26M (yes, you read that right!) 👀
   

Remember that feeling of watching others celebrate their perfect timing in the market? 

Well, grab your coffee, because Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) just dropped news that's turning the biotech world upside down. (1)

(4)

🔥 LYMPHIR Scores Game-Changing Medicare Code! 🔥

Here's the scoop: The Centers for Medicare & Medicaid Services (CMS) just awarded LYMPHIR a permanent J-code (J9161), effective April 1, 2025. (2)(4)

Why does this matter? Because it's like getting a VIP pass to the healthcare system – smoother billing, faster reimbursement, and a clear path to commercial success.

❤️ The Numbers That Make Investors' Hearts Race: (2)(4)

• Market Potential: A stunning $300-400M+ in the U.S. alone
• Projected Revenue: Scaling from $15M in 2025 to $78M+ by 2026
• EPS Growth: From -$5.97 to a projected $4.72 by 2026 (talk about a glow-up!)

🎯 Why LYMPHIR is the Talk of the Town: (2)(4)

• First and only immunotherapy for relapsed/refractory CTCL
• 36% objective response rate, with some patients achieving complete remission
• Serves 3,000-4,000 new U.S. patients annually with no existing cure
• FDA approval already secured (August 2024)

But wait – Citius isn't just a one-hit wonder. They're building an empire with a portfolio that reads like a greatest hits album:

🌟 Mino-Lok®: The $1.8B Market Game-Changer (2)(4)

• Revolutionary antibiotic solution for infected central venous catheters
• Phase 3 trials completed with stellar results
• Targeting 7 million annual U.S. catheter placements
• Could become the new gold standard in infection prevention

🌟 Halo-Lido: The First of Its Kind (2)(4)

• Only prescription hemorrhoid treatment in development
• Phase 2b trials showed impressive symptom reduction
• Target market: 10 million patients, with one-third seeking physician care
• Positioned to dominate a market currently limited to over-the-counter options

🌟 The Hidden Gem: Citius Oncology (NASDAQ: CTOR) (2)(4)

• Citius owns 92% of this focused cancer therapy subsidiary
• Spearheading LYMPHIR's commercialization
• Exploring combinations with blockbuster drugs like KEYTRUDA®
• Potential to unlock multi-billion dollar oncology markets

⏰ Why Time Is of the Essence:

• LYMPHIR commercial launch: First half of 2025
• Founders have invested $26.5M of their own money (that's confidence you can't fake)
• NASDAQ listing stabilized and primed for growth
• Multiple revenue streams coming online

With a 48.07% projected annual earnings growth rate and strong analyst backing, the current price feels like finding Amazon in 1997. (4)

The numbers aren't just impressive – they're screaming "look at me."

🎬 The Decision Point: While others are still debating whether to join the party, industry insiders are already counting their RSVPs. 

The biotech sector moves fast, and opportunities like this don't send save-the-dates. Remember our last feature that popped double digits? Citius Pharmaceuticals (NASDAQ: CTXR) is setting up to be even more exciting.

Remember: The market rewards the bold, but it especially rewards the early. 

Those who see the signals before they become headlines are the ones with the best stories to tell.

Stay ahead. Stay informed. But most importantly – stay in the game. 
 

To your success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://finance.yahoo.com/quote/CTXR/
2. https://bit.ly/432P3oz

3. https://bit.ly/4k5fb8b
4. https://bit.ly/4gtKUhJ

5. https://bit.ly/3XRl7sH

6. https://bit.ly/4hKa1gp
7. https://bit.ly/432Pcs7
8. https://bit.ly/3XN4q1o

Paid Promotion. Momentum Media LLC has been hired for a period beginning on 02/18/2025 and ending on 02/19/2025 (the “Campaign”) to publicly disseminate information about Citius Pharmaceuticals, Inc. (CTXR:US). Momentum Media LLC has been compensated $10,000.00 and are owed an additional $0 for the Campaign. Please read Momentum Media LLC’s complete disclaimer at https://markettips.net/disclaimer/ which includes important information. Emojis, graphics and/or images used herein have no specific or implied meaning, and are used for artistic purposes only. Nothing contained herein is financial advice. Momentum Media LLC is not an analyst, st.o.ck broker, financial adviser or st.o.ck picker nor is it qualified to act in the capacity of any of the foregoing. Information herein is a paid advertisement and should not be relied upon as accurate or complete.